A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa

Pharmacology Research and Perspectives

Volumn 3, Issue 2, 2015, Pages 1-12

  Kang, Sang Bum ^a,b   Marchelletta, Ronald R ^b   Penrose, Harrison ^b   Docherty, Michael J ^b   Mccole, Declan F ^c  

^a The Catholic University of Korea   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biopsy; Chloride secretion; ClC 2; Constipation; Epithelial; Guanylyl cyclase; Irritable bowel syndrome

Indexed keywords

CARBACHOL; CYCLIC AMP; FORSKOLIN; LINACLOTIDE; LUBIPROSTONE;

ADULT; ARTICLE; COLON BIOPSY; COLON MUCOSA; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONSTIPATION; CONTROLLED STUDY; DESENSITIZATION; DRUG EFFICACY; DRUG RESPONSE; ELECTROPHYSIOLOGY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ION TRANSPORT; IRRITABLE COLON; MALE; MIDDLE AGED; PRIORITY JOURNAL; SHORT CIRCUIT CURRENT; TRANSEPITHELIAL RESISTANCE;

EID: 85006949482     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.128     Document Type: Article

References (53)

1. Ao M, Venkatasubramanian J, Boonkaewwan C, Ganesan N, Syed A, Benya RV, et al. (2011). Lubiprostone activates CL- secretion Via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84. Dig Dis Sci 56: 339-351.
2. Bao HF, Liu L, Self J, Duke BJ, Ueno R, Eaton DC (2008). A synthetic prostone activates apical chloride channels in A6 epithelial cells. Am J Physiol Gastrointest Liver Physiol 295: G234-G251.
3. Barish CF, Drossman D, Johanson JF, Ueno R (2010). Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 55: 1090-1097.
4. Barrett KE, Keely SJ (2000). Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol 62: 535-572.
5. Bassil AK, Borman RA, Jarvie EM, McArthur-Wilson RJ, Thangiah R, Sung EZ, et al. (2008). Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 154: 126-135.
6. Bijvelds MJ, Bot AG, Escher JC, De Jonge HR (2009). Activation of intestinal CL- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology 137: 976-985.
7. Blackshaw LA, Brierley SM (2013). Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipation. Expert Rev Gastroenterol Hepatol 7(5 Suppl. 1): 15-19.
8. Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, et al. (2013). Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther 344: 196-206.
9. Catalan M, Niemeyer MI, Cid LP, Sepulveda FV (2004). Basolateral ClC-2 chloride channels in surface colon epithelium: regulation by a direct effect of intracellular chloride. Gastroenterology 126: 1104-1114.
10. Chao AC, de Sauvage FJ, Dong YJ, Wagner JA, Goeddel DV, Gardner P (1994). Activation of intestinal CFTR CL- channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase. EMBO J 13: 1065-1072.
11. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, et al. (2012). Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 107: 1702-1712.
12. Clarke LL (2009). A guide to Ussing chamber studies of mouse intestine. Am J Physiol Gastrointest Liver Physiol 296: G1151-G1166.
13. Clarke LL, Grubb BR, Gabriel SE, Smithies O, Koller BH, Boucher RC (1992). Defective epithelial chloride transport in a gene-targeted mouse model of cystic fibrosis. Science 257: 1125-1128.
14. Cuppoletti J, Malinowska DH, Tewari KP, Li QJ, Sherry AM, Patchen ML, et al. (2004a). SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 287: C1173-C1183.
15. Cuppoletti J, Tewari KP, Sherry AM, Ferrante CJ, Malinowska DH (2004b). Sites of protein kinase a activation of the human ClC-2 CL(-) channel. J Biol Chem 279: 21849-21856.
16. Cuppoletti J, Blikslager AT, Chakrabarti J, Nighot PK, Malinowska DH (2012). Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors. BMC Pharmacol 12: 3.
17. Cuppoletti J, Chakrabarti J, Tewari K, Malinowska DH (2013). Methadone but not morphine inhibits lubiprostone-stimulated CL- currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR CL- currents. Cell Biochem Biophys 66: 53-63.
18. Cuppoletti J, Chakrabarti J, Tewari KP, Malinowska DH (2014). Differentiation between human ClC-2 and CFTR CL- Channels with pharmacological agents. Am J Physiol Cell Physiol 307: C479-C492.
19. Cuthbert AW, Hickman ME, MacVinish LJ (1999). Formal analysis of electrogenic sodium, potassium, chloride and bicarbonate transport in mouse colon epithelium. Br J Pharmacol 126: 358-364.
20. Dharmsathaphorn K, Pandol SJ (1986). Mechanism of chloride secretion induced by carbachol in a colonic epithelial cell line. J Clin Invest 77: 348-354.
21. Fei G, Wang YZ, Liu S, Hu HZ, Wang GD, Qu MH, et al. (2009). Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon. Am J Physiol Gastrointest Liver Physiol 296: G823-G832.
22. Field M, Graf LH Jr, Laird WJ, Smith PL (1978). Heat-stable enterotoxin of Escherichia Coli: in vitro effects on guanylate cyclase activity, cyclic GMP concentration, and ion transport in small intestine. Proc Natl Acad Sci USA 75: 2800-2804.
23. Giannella RA, Drake KW (1979). Effect of purified escherichia coli heat-stable enterotoxin on intestinal cyclic nucleotide metabolism and fluid secretion. Infect Immun 24: 19-23.
24. Ginzburg R, Ambizas EM (2008). Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders. Expert Opin Drug Metab Toxicol 4: 1091-1097.
25. Gyomorey K, Yeger H, Ackerley C, Garami E, Bear CE (2000). Expression of the chloride channel ClC-2 in the murine small intestine epithelium. Am J Physiol Cell Physiol 279: C1787-C1794.
26. Han X, Mann E, Gilbert S, Guan Y, Steinbrecher KA, Montrose MH, et al. (2011). Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier. PLoS One 6: e16139.
27. Hemlin M, Jodal M, Lundgren O, Sjovall H, Stage L (1988). The importance of the subepithelial resistance for the electrical properties of the rat jejunum in vitro. Acta Physiol Scand 134: 79-88.
28. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R (2008a). Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 27: 685-696.
29. Johanson JF, Morton D, Geenen J, Ueno R (2008b). Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 103: 170-177.
30. Johnston JM, Kurtz CB, Drossman DA, Lembo AJ, Jeglinski BI, MacDougall JE, et al. (2009). Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 104: 125-132.
31. Layer P, Stanghellini V (2014). Review article: linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 39: 371-384.
32. Li Z, Goy MF (1993). Peptide-regulated guanylate cyclase pathways in rat colon: in situ localization of GCA, GCC, and Guanylin mRNA. Am J Physiol 265(2 Pt. 1): G394-G402.
33. Lin JE, Snook AE, Li P, Stoecker BA, Kim GW, Magee MS, et al. (2012). GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. PLoS One 7: e31686.
34. Lorenz JN, Nieman M, Sabo J, Sanford LP, Hawkins JA, Elitsur N, et al. (2003). Uroguanylin knockout mice have increased blood pressure and impaired natriuretic response to enteral nacl load. J Clin Invest 112: 1244-1254.
35. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, et al. (2000). Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52: 375-414.
36. MacVinish LJ, Cope G, Ropenga A, Cuthbert AW (2007). Chloride transporting capability of Calu-3 epithelia following persistent knockdown of the cystic fibrosis transmembrane conductance regulator, CFTR. Br J Pharmacol 150: 1055-1065.
37. Mall M, Bleich M, Schurlein M, Kuhr J, Seydewitz HH, Brandis M, et al. (1998). cholinergic ion secretion in human colon requires coactivation by cAMP. Am J Physiol 275: G1274-G1281.
38. Martin S, Adermann K, Forssmann WG, Kuhn M (1999). Regulated, side-directed secretion of proguanylin from isolated rat colonic mucosa. Endocrinology 140: 5022-5029.
39. McCole DF, Rogler G, Varki N, Barrett KE (2005). Epidermal growth factor partially restores colonic ion transport responses in mouse models of chronic colitis. Gastroenterology 129: 591-608.
40. McWilliams V, Whiteside G, McKeage K (2012). Linaclotide: first global approval. Drugs 72: 2167-2175.
41. Metzger H, Lindner E (1981). The positive inotropic-acting forskolin, a potent adenylate cyclase activator. Arzneimittelforschung 31: 1248-1250.
42. Moeser AJ, Haskell MM, Shifflett DE, Little D, Schultz BD, Blikslager AT (2004). ClC-2 chloride secretion mediates prostaglandin-induced recovery of barrier function in ischemia-injured porcine ileum. Gastroenterology 127: 802-815.
43. Moeser AJ, Nighot PK, Engelke KJ, Ueno R, Blikslager AT (2007). Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol 292: G647-G656.
44. Moeser AJ, Nighot PK, Roerig B, Ueno R, Blikslager AT (2008). Comparison of the chloride channel activator lubiprostone and the oral laxative polyethylene glycol 3350 on mucosal barrier repair in ischemic-injured porcine intestine. World J Gastroenterol 14: 6012-6017.
45. Nighot PK, Blikslager AT (2012). Chloride channel ClC-2 modulates tight junction barrier function via intracellular trafficking of occludin. Am J Physiol Cell Physiol 302: C178-C187.
46. Pena-Munzenmayer G, Catalan M, Cornejo I, Figueroa CD, Melvin JE, Niemeyer MI, et al. (2005). Basolateral localization of native ClC-2 chloride channels in absorptive intestinal epithelial cells and basolateral sorting encoded by a CBS-2 domain di-leucine motif. J Cell Sci 118: 4243-4252.
47. Pitari GM, Li P, Lin JE, Zuzga D, Gibbons AV, Snook AE, et al. (2007). The paracrine hormone hypothesis of colorectal cancer. Clin Pharmacol Ther 82: 441-447.
48. Schechter MD (1997). Discrete versus cumulative dosing in dose-response discrimination studies. Eur J Pharmacol 326: 113-118.
49. Schey R, Rao SS (2011). Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci 56: 1619-1625.
50. Swenson ES, Mann EA, Jump ML, Witte DP, Giannella RA (1996). The guanylin/STa receptor is expressed in crypts and apical epithelium throughout the mouse intestine. Biochem Biophys Res Commun 225: 1009-1014.
51. Vaandrager AB, Bot AG, De Jonge HR (1997). Guanosine 3′, 5′-cyclic monophosphate-dependent protein kinase II mediates heat-stable enterotoxin-provoked chloride secretion in rat intestine. Gastroenterology 112: 437-443.
52. Vaandrager AB, Bot AG, Ruth P, Pfeifer A, Hofmann F, De Jonge HR (2000). Differential role of cyclic GMP-dependent protein kinase II in ion transport in murine small intestine and colon. Gastroenterology 118: 108-114.
53. Vaandrager AB, Hogema BM, de Jonge HR (2005). Molecular properties and biological functions of cGMP-dependent protein kinase II. Front Biosci 10: 2150-2164.